The effects of sorafenib in healthy and cisplatin-treated rats

Basit Öğe Kaydı
dc.contributor.authorDemirtas, Levent
dc.contributor.authorGürbüzel, Mehmet
dc.contributor.authorTahirler, Hilal
dc.contributor.authorAkbas, Emin Murat
dc.contributor.authorKaratas, Ozhan
dc.contributor.authorArslan, Yusuf Kemal
dc.date.accessioned2025-05-04T16:41:56Z
dc.date.available2025-05-04T16:41:56Z
dc.date.issued2023
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractBackground. Sorafenib is a multikinase inhibitor currently used in the treatment of hepatocellular carcinoma, renal cell carcinoma and thyroid cancer. Objectives. The literature on this agent is scarce. This study aimed to evaluate the effects of sorafenib when administered to both healthy and cisplatin-induced rats. Materials and methods. The animals were divided into 4 groups: 1) control group that received 0.9% saline intraperitoneally (C); 2) group administered a single dose (7 mg/kg) of cisplatin (Cis); 3) a group administered 20 mg/kg of sorafenib for 7 days (Sor); 4) group administered 20 mg/kg of sorafenib followed by 7 mg/kg of cisplatin for 7 days (Cis+Sor). All animals were sacrificed 7 days after the completion of their treatment arm, and serum and tissue samples were taken. Results. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and interleukin 38 (IL-38) levels were increased in the Sor and Cis+Sor groups compared to the control group. When compared with the control group, serum urea, creatinine, kidney IL-1β, and tumor necrosis factor alpha (TNF-α) levels did not change in the Sor group. When compared to the Cis group, the levels of these parameters decreased in the Cis+Sor group. Conclusions. According to the data obtained, sorafenib caused liver toxicity when given to both healthy and cisplatin-induced rats. While sorafenib did not cause any significant changes in the kidneys when given to healthy rats, it had a healing effect in kidneys after stress induced by cisplatin. © 2023 Wroclaw University of Medicine. All rights reserved.
dc.description.sponsorshipResearch Fund of Erzincan Binali Yıldırım University, (SAG-A-070114-0051)
dc.identifier.doi10.17219/acem/155216
dc.identifier.endpage456
dc.identifier.issn1899-5276
dc.identifier.issue4
dc.identifier.pmid36413179
dc.identifier.scopus2-s2.0-85146788442
dc.identifier.scopusqualityQ1
dc.identifier.startpage449
dc.identifier.urihttps://doi.org/10.17219/acem/155216
dc.identifier.urihttps://hdl.handle.net/20.500.12418/34992
dc.identifier.volume32
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWroclaw University of Medicine
dc.relation.ispartofAdvances in Clinical and Experimental Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_Scopus_20250504
dc.subjectcisplatin
dc.subjectIL-38
dc.subjectnephrotoxicity
dc.subjectrat
dc.subjectsorafenib
dc.titleThe effects of sorafenib in healthy and cisplatin-treated rats
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu